Author: Ferrucci, SM; Tavecchio, S; Favale, EM; Angileri, L; Riva, D; Romagnuolo, M; Beretta, AE; Marzano, A V
Title: Effects of lockdown on health of patients with severe atopic dermatitis treated with dupilumab Cord-id: vvli6vbd Document date: 2020_9_25
ID: vvli6vbd
Snippet: use of dupilumab as treatment for severe adult atopic dermatitis (AD) increased over time since its introduction in September 2018, due to its established efficacy. AD is one of the most common chronic inflammatory skin disease affecting up to 14.3% of adults, with 63,3% of these cases first appearing before 18 years of age. Patients’ disease burden is important with high rate of discomfort, less confidence in daily life activities and psychoâ€social distress. The introduction of dupilumab ch
Document: use of dupilumab as treatment for severe adult atopic dermatitis (AD) increased over time since its introduction in September 2018, due to its established efficacy. AD is one of the most common chronic inflammatory skin disease affecting up to 14.3% of adults, with 63,3% of these cases first appearing before 18 years of age. Patients’ disease burden is important with high rate of discomfort, less confidence in daily life activities and psychoâ€social distress. The introduction of dupilumab changed the natural history of this disease, drastically improving AD manifestations and therefore quality of life.
Search related documents:
Co phrase search for related documents- lockdown phase and lombardy region: 1, 2, 3
- lockdown time and lombardy region: 1, 2
- lockdown time and loss contagion: 1
Co phrase search for related documents, hyperlinks ordered by date